Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03380377Phase 1Completed

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Role: lead

NCT03380962Phase 1Active Not Recruiting

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Role: lead

NCT01178216Phase 1Completed

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Role: lead

NCT01134510Phase 1Completed

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Role: lead

All 4 trials loaded